GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

ECC4703

Company
Eccogene
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
3 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

3 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for ECC4703 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07288138

    A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

    Not yet reported Eccogene 160 participants Est. completion 2027-09-29 64 sites Stand-alone
    MASH
    View official trial listing →
  • Recruiting NCT NCT07334080

    ECC4703 Food Effect and Relative Bioavailability Study in Healthy Adult Participants

    Not yet reported Eccogene 72 participants Est. completion 2027-04 1 site Stand-alone
    MASH
    View official trial listing →
  • Recruiting NCT NCT07726368

    Study of ECC4703 With Sulfasalazine and Pitavastatin

    Not yet reported Eccogene 40 participants Est. completion 2026-12 1 site Stand-alone
    MASLD Other conditions: Dyslipidaemia
    View official trial listing →
  • Completed NCT NCT05552274

    FTIH of ECC4703 in Healthy Volunteers

    Not yet reported Eccogene 75 participants Est. completion 2023-10-26 1 site Stand-alone
    MASH
    View official trial listing →
  • Active, not recruiting NCT NCT07505303

    MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

    Not yet reported Eccogene 151 participants Est. completion 2026-10-15 15 sites Added to GLP-1
    Other conditions: Adult Obesity, Weight Management
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.